Objectives To compare CYP2C19 enzyme activity between Swedes and Koreans controlling for the effect of CYP2C19 genotype, sex, oral contraceptive use, and smoking habits. Methods CYP2C19 activity was determined in 185 healthy Swedish and 150 Korean subjects as the omeprazole/5-hydroxyomeprazole ratio (metabolic ratio; MR) using high-performance liquid chromatography. Genotyping was performed by PCR using Taqman assay. Results As expected, a higher incidence of poor metabolizers (PM) was found in Koreans (14%) compared with Swedes (3.8%) and the frequency of the CYP2C19*17 allele was very low in Koreans (0.3%). Among subjects homozygous for CYP2C19*1, Koreans displayed significantly lower CYP2C19 enzyme activity than Swedes (p<0.000001). Interestingly, in Koreans a pronounced gender difference was apparent: females (n=24) had significantly lower MR than males (n=30; p<0.0001), but such a gender difference was not seen among Swedes. Swedish OC users had a higher MR than non-users (p<0.00001), whereas OC was only used by one Korean. No effects of smoking were observed.
Introduction
The enzyme CYP2C19 catalyzes the metabolism of a wide variety of drugs such as antidepressants [1] , benzodiazepines [2] , proguanil [3] , and proton pump inhibitors (PPIs) [4] . The major metabolites of omeprazole detected in vivo in human plasma are 5-hydroxyomeprazole formed by CYP2C19 and omeprazole sulfone formed by CYP3A4 [5, 6] . The metabolic disposition of omeprazole correlates well with the rate of S-mephenytoin hydroxylation [7] and those two drugs are the most commonly used probes of CYP2C19. About 3% of Caucasians are poor metabolizers (PM) of S-mephenytoin [8, 9] and a higher incidence of PMs has been reported in Japanese (18-23%) [10, 11] , Chinese (15-17%) [12, 13] , and in Korean subjects (13-16%) [14] . The PM phenotype is caused by the CYP2C19*2 [15] and CYP2C19*3 alleles, although the CYP2C19*3 is very uncommon in Caucasian PMs [16] . Sim et al. [17] identified a novel allele (CYP2C19*17) that was associated with increased CYP2C19 activity in vivo in two different ethnic populations. This allele is associated with higher levels of gene transcription and increased rates of omeprazole and mephenytoin metabolism. The frequency of this allele was 18% in both Swedes and Ethiopians, but only 4% in Chinese subjects [17] .
In general previous studies reported lower CYP2C19 enzyme activity among Asians compared with whites. Several factors may contribute to the observed inter-ethnic differences in enzyme activity, such as differences in functional variant allele frequencies between populations and other environmental factors like dietary, oral contraceptive (OC) use or smoking habits. Indeed CYP2C19 defective variant alleles occur at a higher frequency in Asians than in whites and this may account partly for the lower CYP219 activity observed in this population. Furthermore, previously it has been reported that OC use inhibits CYP2C19 enzyme activity [18] and hence variation in OC use habit may also contribute to some extent. As to our knowledge no study has compared the enzyme activity between the two populations controlling for the effect of confounding factors such as oral contraceptive use and CYP2C19 genotype. The aim of the present study was to investigate the CYP2C19 genotype-phenotype relationship differences using the same methodology between healthy Swedish and Korean subjects with the same CYP2C19 genotype, OC use, and smoking habits. We find an important gender difference in the CYP2C19 activity in Koreans, but not in Swedes and generally lower CYP2C19 activity among Koreans in subjects homozygous for CYP2C19*1.
Materials and methods

Study subjects
We studied 185 healthy Swedish subjects at the Karolinska University Hospital, Huddinge, Sweden and 150 healthy Korean subjects at the Inha University Hospital, Incheon, Korea. The subjects were mainly students and staff at the two Hospitals. In the Swedish subjects the mean age was 29 ± SD 8.3 years (range 18-60) with the mean weight 69 ± SD 12 kg (range 47-109; no data on weight in 2 subjects). The Swedish subjects consisted of 112 women and 73 men and 39 (11 men and 28 women) were classified as smokers (definition of smokers > 2 cigarettes/day) as described previously [19, 20] . There were 44 women using OC. Among the 28 women smokers, 6 were OC users. In 4 women no data on OC use were available. In the Korean subjects the mean age was 25 ±3.9 years (range 20-46) with the mean weight 62 ± 12 kg (range 38-94). The Korean subjects consisted of 74 women and 76 men and 29 of the subjects were classified as smokers (26 men and 3 women of whom none were OC users). In 1 subject information on smoking habit was unavailable. Only 1 Korean woman was a user of OC. The participants were asked if they used OC, but not which kind of contraceptives they used.
The local Ethics committees at Karolinska Institutet, Stockholm, Sweden and Inha University, Incheon, Korea approved the study and it was performed in accordance with the Helsinki Declaration. After written and oral information about the study, the participants were screened by clinical laboratory tests and interviewed with regard to their medical histories. The subjects were not allowed to use other medications (except for OC) including herbal medicines 1 week before the study started. They refrained from alcohol and grapefruit juice for 2 days and caffeine products for 1.5 days before the study started. The Karolinska cocktail included omeprazole (20 mg; enteric tablet of Losec MUPS [20 mg] ; Hässle, Stockholm, Sweden), losartan (25 mg), caffeine (100 mg), quinine (250 mg), and debrisoquine (10 mg) [21] .
Phenotyping
After an 8-h overnight fast, the subjects took the drug omeprazole at 8 a.m. Three hours after the intake of omeprazole, blood samples were collected and centrifuged, plasma was separated and stored frozen at -20°until analysis by reversed phase HPLC with UV detection. The Korean plasma and DNA samples were packed on dry ice and sent to Sweden for analysis. The method for measuring omeprazole and its metabolite 5-hydroxyomeprazole was described by Tybring et al. [22] and modified by Christensen et al. [21] .
Genotyping
Blood samples were collected using tubes containing EDTA. Genomic DNA was extracted from leukocytes by using QIAamp®DNA Mini Blood Kit (distributed by AB Applied Biosystems, Foster City, CA, USA and Chestrite, UK). Genotyping methods are based on the PCR (polymerase chain reaction) technique and specific primers to different parts of the gene. Allelic discrimination was determined by using a Taqman assay. Genotyping of CYP2C19*17 was carried out by PCR with specific primers as described by Sim et al. [17] .
Statistical analysis
The individual metabolic ratio MR of omeprazole was determined by dividing the molar concentrations of omeprazole and 5-hydroxyomeprazole in plasma.
The MRs were log transformed before application of statistical analysis. For comparisons of Swedes and Koreans within each genotype group and between groups based on smoking and OC use the independent t test was used. P values less than 0.05 were considered statistically significant. Statistical analyses were performed by Statistical version 7 (Stat Soft® Scandinavia AB, Uppsala, Sweden).
Results
CYP2C19 genotype
The study encompassed 185 Swedes and 150 Koreans. We evaluated results after administering the Karolinska cocktail with the use of omeprazole as a probe drug for phenotyping of CYP2C19. The genotype analyses revealed allele frequencies of CYP2C19*2 and *17 in the Swedes of 16 and 20% respectively and 28, 11, and 0.3% of *2, *3, and *17 in the Koreans respectively (Table 1 ). In both Koreans and Swedes, there was no significant difference between the observed and expected genotype frequency according to the Hardy-Weinberg law (χ 2 test, p>0.05).
CYP2C19 phenotype
The subjects were phenotyped for omerazole and Fig. 1 For statistical analysis and comparison of CYP2C19 enzyme activity, subjects were first stratified based on the CYP2C19 genotype. The subjects homozygous for CYP2C19*1 were further stratified for gender and intake of OC (Fig. 2) . Interestingly, the Koreans homozygous for CYP2C19*1 had significantly higher MR for omeprazole; the MR in Korean men was 1.91 vs 0.56 in Swedish men (p<0.000001) and an MR of 0.91 was seen in Korean females subjects compared with 0.58 in Swedish women who were non-OC users (p= 0.022). In Koreans, a gender difference was seen where men (n=30) had higher MR (1.91) compared with female subjects (n=24; 0.91; p<0.0001). By contrast, no gender differences were seen among the Swedes. Among the Swedish women, OC had a pronounced inhibitory effect (p<0.00001), whereas no Korean female on OC was included in the study, since OC usage was only reported by one Korean woman. The results of the phenotyping of the two populations are also shown stratified according to the number of active genes (excluding CYP2C19*17) with the two genders together (Fig. 3) . Korean subjects homozygous for CYP2C19*1 had much higher MR (1.48) than the Swedish individuals (0.58; p<0.000001). A similar difference was also noted when comparing those with one functional allele (2.88 vs 1.10, p<0.0012) and also a small difference (28.8 vs 20.9, p<0.028) was noted among those homozygous for null alleles, although the number of subjects in the Swedish *0/*0 group is very low.
The CYP2C19*17 allele was only present in one Korean subject. Analysis of the MR for omeprazole among Swedes revealed that the MR in *17/ *17 was significantly lower (0.18, n=4) than in *1/ *1 (0.58, n=56, p=0.016) and *1/ *17 (0.51, n=35; p=0.048), in line with our previous results [17] .
There was no effect of smoking on MR neither in Swedes (p=0.75) nor in Koreans (p=0.50) in the genotype CYP2C19 *1/ *1 by using the independent t test. Considering smokers and non-smokers separately, effect of the CYP2C19 genotype on enzyme activity remained significant in both Koreans (p< 0.0001) and Swedes (p<0.0003). We further investigated the interaction among genotype, oral contraceptive use and smoking using factorial ANOVA in Swedes. Since there was only one OC user in Koreans we did not perform this analysis in Koreans. The result indicated only oral contraceptive use (p<0.001) and CYP2C19 genotype (p<0.001), but not smoking affects CYP2C19 activity. Regardless of smoking habit, oral contraceptive use inhibited and CYP2C19 genotype influenced CYP2C19 enzyme activity.
Discussion
In the present study we compared CYP2C19 enzyme activity between Koreans and Swedes using the same methodology and taking into consideration the effect of genotype, sex, and OC use. Our major findings include quite unexpected and very interesting differences in the CYP2C19 phenotype between Koreans and Swedes belonging to the same genotype group, namely those homozygous for CYP2C19*1. Phenotyping data based on the probe drug omeprazole revealed that the Korean men had a much higher MR for omeprazole than the Swedish men. Interestingly, Korean women had significantly more rapid omeprazole metabolism than the Korean men. Still, the Korean women had slower omeprazole metabolism than the Swedish women who were not taking oral contraceptives, but the difference was much less than that observed between Swedish and Korean men. Oral contraceptive intake did decrease the rate of omeprazole metabolism in Swedish women to approach a similar MR for omeprazole to that of Korean men. Korean subjects carrying one null allele also had a slower omeprazole metabolism compared with Swedes and a slight difference was seen between men and women who were homozygous for null alleles (Fig. 3 ), but this difference was very small and the number of Swedish subjects in this group was also very low. Stratifying the phenotype data with regard to smokers or non-smokers revealed no influence of smoking habit on CYP2C19 enzyme activity. Previously, a small, barely significant gender difference in CYP2C19 activity was observed in Chinese using Smephenytoin as a probe drug [23] . Here, the S/R-ratio for mephenytoin was lower in homozygous extensive metabolizer (EM) females than in homozygous EM males (0.22 ± 0.14 vs 0.33 ± 0.09; p=0.046). By using omeprazole as a probe drug in the current study in Koreans, much higher significance values were obtained for a gender difference, indicating that such a gender difference is true in some Asian populations.
The mechanism behind the gender difference in Koreans in CYP2C19 activity is unknown. One could imagine environmental, epigenetic or genetic reasons. Regarding environmental influences, differences in diets or drug habits between Korean men and women are unlikely, but could not be excluded. Also, one could hypothesize that hormonal or environmental influences should result in gender-specific epigenetic control of CYP2C19 gene expression, which would influence the activity. This cannot be excluded and a true evaluation would require liver samples from both sexes where the pattern of gene methylation as well as histone acetylation and methylation could be investigated [24] . Perhaps the most likely explanation is of true genetic origin. The differences in sequence between the Caucasian and Korean CYP2C locus, as revealed from whole genome sequencing in the CYP2C locus, are extensive and encompass several hundreds of mutations [25] . One could therefore suggest that the Korean variant of the CYP2C19*1 allele carries mutations that make expression lower compared with the Swedish variant, and at the same time there are mutations in this locus that make the Korean CYP2C19*1 gene more sensitive to the estrogen receptor or other nuclear factors controlled by the action of estrogens, thereby causing an increased rate of CYP2C19 activity in the Korean female subjects compared to the male subjects. Further studies have to be designed that investigate these alternatives before the basis of the gender difference is understood.
The Swedish female subjects taking OCs had lower CYP2C19 activity than women without. Tamminga et al. have also described an effect of OCs using S-mephenytoin as a probe drug [26] . The OCs may contain progestin with or without ethinyl estradiol and it is not known whether it is the estrogen or the progestin component that inhibits drug metabolism [10] . The inhibition of CYP2C19 activity by OCs seems to be due to the ethinylestradiol component of OCs [27, 28] . The mechanism behind this effect is unknown, but has been suggested to be interaction at the active site between the hormones and the CYP2C19 substrates. A mechanism where the oral contraceptives directly inhibit the rate of CYP2C19 expression can, however, not be excluded.
Our result indicated no significant effect of cigarette smoking on CYP2C19 enzyme activity in both populations. Even controlling for the effect of genotype and OC use there was no significant difference between smokers and nonsmokers regarding enzyme activity. Among cytochrome P450 drug-metabolizing enzymes that are expressed in the liver, CYP1A2 is the only one whose activity is affected by smoking habits [20] . Previous studies reported interaction between smoking and the CYP2C19 genotype in influencing H. pylori eradication success and suggested the interaction between smoking and CYP2C19 should be examined in the future [29] . Apparently, the effect of smoking on H. pylori eradication might be not by directly altering CYP2C19 enzyme activity and hence omeprazole metabolism. The finding of significantly lower CYP2C19 enzyme activity in Koreans compared with Swedes that is not accountable or explained by the common CYP2C19 genotype or OC use may have some clinical relevance. In clinical practice the common CYP2C19 SNPs that are recommended or practiced to genotype for include CYP2C19*2 and *3 in Asians. Our study indicates genotyping for these SNPs only may not provide full information about an individual's metabolic capacity or phenotype. Alternatively, phenotyping with a safe probe drug to reflect an individual´s metabolic capacity or therapeutic drug monitoring may need to be considered. Our study can also be a base for further investigation to identify the underlying genetic, epigenetic or environmental factors responsible for the wide differences observed in CYP2C19 enzyme activity between Koreans and Swedes.
Limitations of present study include the fact that subjects were genotyped for the most common variant alleles in the respective population and other variants of the CYP2C19 alleles were not analyzed because of their low frequencies. However, the contribution of these rare variant alleles to the difference observed in enzyme activity between the two populations cannot be ruled out. In summary, the present study describes an interesting gender difference in the CYP2C19 enzyme activity in Koreans that cannot be seen in Swedes. Further studies are needed to evaluate the mechanisms behind this difference, which, however, would drastically influence the pharmacokinetics of CYP2C19 drugs to motivate gender-specific dosing regimens in Koreans.
